A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
NevGold Announces Up To 53.7% Antimony, And Fourteen Samples Over 2% Antimony, From Surface Sampling On Pre-Strip Dump
TomaGold Completes Extension Drilling Program at Berrigan Mine and Launches Major Prospecting and Geophysical Survey Campaign Across its Chibougamau Properties
